450 related articles for article (PubMed ID: 33007410)
1. Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope.
Zafar A; Wang W; Liu G; Xian W; McKeon F; Zhou J; Zhang R
Cancer Lett; 2021 Jan; 496():16-29. PubMed ID: 33007410
[TBL] [Abstract][Full Text] [Related]
2. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.
Gamble LD; Kees UR; Tweddle DA; Lunec J
Oncogene; 2012 Feb; 31(6):752-63. PubMed ID: 21725357
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
4. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.
Chen Z; Lin Y; Barbieri E; Burlingame S; Hicks J; Ludwig A; Shohet JM
Neoplasia; 2009 Aug; 11(8):753-62. PubMed ID: 19649205
[TBL] [Abstract][Full Text] [Related]
5. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.
Lu J; Guan S; Zhao Y; Yu Y; Wang Y; Shi Y; Mao X; Yang KL; Sun W; Xu X; Yi JS; Yang T; Yang J; Nuchtern JG
Oncotarget; 2016 Dec; 7(50):82757-82769. PubMed ID: 27764791
[TBL] [Abstract][Full Text] [Related]
6. Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma.
Chen L; Rousseau RF; Middleton SA; Nichols GL; Newell DR; Lunec J; Tweddle DA
Oncotarget; 2015 Apr; 6(12):10207-21. PubMed ID: 25844600
[TBL] [Abstract][Full Text] [Related]
7. Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma.
Chen L; Zhao Y; Halliday GC; Berry P; Rousseau RF; Middleton SA; Nichols GL; Del Bello F; Piergentili A; Newell DR; Lunec J; Tweddle DA
Br J Cancer; 2014 Aug; 111(4):716-25. PubMed ID: 24921920
[TBL] [Abstract][Full Text] [Related]
8. MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance.
Barone G; Tweddle DA; Shohet JM; Chesler L; Moreno L; Pearson AD; Van Maerken T
Curr Drug Targets; 2014 Jan; 15(1):114-23. PubMed ID: 24387312
[TBL] [Abstract][Full Text] [Related]
9. Low p14ARF expression in neuroblastoma cells is associated with repressed histone mark status, and enforced expression induces growth arrest and apoptosis.
Dreidax D; Gogolin S; Schroeder C; Muth D; Brueckner LM; Hess EM; Zapatka M; Theißen J; Fischer M; Ehemann V; Schwab M; Savelyeva L; Westermann F
Hum Mol Genet; 2013 May; 22(9):1735-45. PubMed ID: 23343716
[TBL] [Abstract][Full Text] [Related]
10. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
[TBL] [Abstract][Full Text] [Related]
11. Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma.
He J; Gu L; Zhang H; Zhou M
Cell Cycle; 2011 Sep; 10(17):2994-3002. PubMed ID: 21862876
[TBL] [Abstract][Full Text] [Related]
12. Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14(ARF)-MDM2-p53 axis.
Van Maerken T; Vandesompele J; Rihani A; De Paepe A; Speleman F
Cell Death Differ; 2009 Dec; 16(12):1563-72. PubMed ID: 19779493
[TBL] [Abstract][Full Text] [Related]
13. High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma.
Carr-Wilkinson J; O'Toole K; Wood KM; Challen CC; Baker AG; Board JR; Evans L; Cole M; Cheung NK; Boos J; Köhler G; Leuschner I; Pearson AD; Lunec J; Tweddle DA
Clin Cancer Res; 2010 Feb; 16(4):1108-18. PubMed ID: 20145180
[TBL] [Abstract][Full Text] [Related]
14. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma.
Van Maerken T; Speleman F; Vermeulen J; Lambertz I; De Clercq S; De Smet E; Yigit N; Coppens V; Philippé J; De Paepe A; Marine JC; Vandesompele J
Cancer Res; 2006 Oct; 66(19):9646-55. PubMed ID: 17018622
[TBL] [Abstract][Full Text] [Related]
15. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death.
Barbieri E; Mehta P; Chen Z; Zhang L; Slack A; Berg S; Shohet JM
Mol Cancer Ther; 2006 Sep; 5(9):2358-65. PubMed ID: 16985070
[TBL] [Abstract][Full Text] [Related]
16. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
17. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.
Burmakin M; Shi Y; Hedström E; Kogner P; Selivanova G
Clin Cancer Res; 2013 Sep; 19(18):5092-103. PubMed ID: 23864164
[TBL] [Abstract][Full Text] [Related]
18. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
19. The role of p53 in cancer drug resistance and targeted chemotherapy.
Hientz K; Mohr A; Bhakta-Guha D; Efferth T
Oncotarget; 2017 Jan; 8(5):8921-8946. PubMed ID: 27888811
[TBL] [Abstract][Full Text] [Related]
20. Targeted molecular therapy for neuroblastoma: the ARF/MDM2/p53 axis.
Kim E; Shohet J
J Natl Cancer Inst; 2009 Nov; 101(22):1527-9. PubMed ID: 19903809
[No Abstract] [Full Text] [Related]
[Next] [New Search]
